These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 19087143)
1. Can we get rid of neutralizing antibodies against interferon-β? Buttmann M; Toyka KV Eur J Neurol; 2009 Jan; 16(1):7-9. PubMed ID: 19087143 [No Abstract] [Full Text] [Related]
2. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832 [TBL] [Abstract][Full Text] [Related]
3. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β. Hesse D; Frederiksen JL; Koch-Henriksen N; Schreiber K; Stenager E; Heltberg A; Ravnborg M; Bendtzen K; Sellebjerg F; Sorensen PS Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149 [TBL] [Abstract][Full Text] [Related]
4. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Bojar M; Zajac M; Meluzínová E; Houžvičková E; Libertinová J; Lišková P; Mat'oška V; Nyč O; Mináriková M Mult Scler; 2010 Dec; 16(12):1529-30; author reply 1531-2. PubMed ID: 20829243 [No Abstract] [Full Text] [Related]
5. The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies. Giantzi V; Karapanayiotides T; Lagoudaki R; Poulatsidou KN; Lourbopoulos A; Daniilidis M; Taskos N; Milonas I; Grigoriadis N Eur Neurol; 2016; 75(1-2):82-8. PubMed ID: 26867030 [TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab. Sørensen PS; Koch-Henriksen N; Jensen PE Neurology; 2011 Feb; 76(8):759-60. PubMed ID: 21339504 [No Abstract] [Full Text] [Related]
7. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic. Zarkou S; Carter JL; Wellik KE; Demaerschalk BM; Wingerchuk DM Neurologist; 2010 May; 16(3):212-4. PubMed ID: 20445436 [TBL] [Abstract][Full Text] [Related]
8. Interferon neutralizing antibodies in multiple sclerosis: a new perspective. Phillips JT Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901 [No Abstract] [Full Text] [Related]
9. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta. Lundkvist M; Greiner E; Hillert J; Fogdell-Hahn A Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645 [TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al. Menge T; Hartung HP; Kieseier BC J Neurol; 2011 May; 258(5):904-7. PubMed ID: 21340521 [No Abstract] [Full Text] [Related]
11. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis]. Seres E; Vécsei L Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710 [TBL] [Abstract][Full Text] [Related]
12. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis. Bendtzen K J Interferon Cytokine Res; 2010 Oct; 30(10):759-66. PubMed ID: 20874253 [TBL] [Abstract][Full Text] [Related]
13. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. van Beers MM; Jiskoot W; Schellekens H J Interferon Cytokine Res; 2010 Oct; 30(10):767-75. PubMed ID: 20874254 [TBL] [Abstract][Full Text] [Related]
15. [The methods of detection of binding and neutralizing antibodies to preparations of interferon-beta]. Nazarov VD; Lapin SV; Surkova EA; Makshakov GS; Mazing AV; Evdoshenko EP; Totolian AA Klin Lab Diagn; 2016 Oct; 61(10):710-4. PubMed ID: 30615336 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress? Carlson RJ; Doucette JR; Knox K; Nazarali AJ Cytokine Growth Factor Rev; 2015 Apr; 26(2):249-61. PubMed ID: 25524087 [TBL] [Abstract][Full Text] [Related]